

14 February 2017

ASX Code: MXC

Medical Cannabis Clinical Study Commencing with World Leading Epilepsy Physicians

Development of Proprietary Epilepsy Formula for MXC Pharmaceuticals

- MGC Pharmaceuticals to commence a clinical study to assess the efficacy of a medicinal cannabis formulation in children and adolescents with treatment-resistant epilepsy
- Study brings together two globally renowned epilepsy experts, Dr David Neubauer and MXC Advisory Board member, Professor Uri Kramer to oversee the clinical test program
- Over 65 volunteers already recruited to the 6-week study, with a large pool of potential volunteers that have expressed an interest in participating
- Results from the study will be instrumental in the Company's development of its own proprietary pharmaceutical grade product for epilepsy treatments
- Potential for future clinical studies globally to use Company's own proprietary formula and dosage
- The registration and sale of a pharmaceutical product for the treatment of epilepsy presents a significant commercial opportunity

MGC Pharmaceuticals Ltd (ASX: MXC or "the Company") is pleased to confirm that it is commencing a clinical study following the signing of a binding research agreement with the University Children's Hospital Ljubljana for a Phase IIA Crossover (non-pivotal) clinical study. The study uses enriched medical cannabis products in children and adolescents with treatment-resistant epilepsy at the Hospital's Department of Adolescent & Developmental Neurology. The research has also received approval from the Hospital Ethics Committee for the study.

Over 65 patients have already been recruited to participate in the 6-week study, with a total of 70 volunteers required to achieve statistical significance. The Company has a large pool of over 150 potential volunteers that have expressed an interest in participating.

Under the direction of Dr Neubauer, the Phase IIA Crossover (non-pivotal) study aims to assess the efficacy of MGC Pharmaceuticals' medicinal cannabis formulation, a whole plant extract based medicine with high CBD/THC ratio, and compare it to pure synthetic CBD. The primary end point of the study will be a reduction in the frequency of seizures experienced by individuals suffering from epilepsy.

A
S
X

R
E
L
E
A
S
E

Study Led by World Leaders in Epilepsy

The study is being led by two globally renowned epilepsy experts, Dr David Neubauer and MXC strategic advisory board member, Professor Uri Kramer, who have both previously conducted ground breaking clinical studies targeting epilepsy with medical cannabis. Dr Neubauer is a paediatric specialist whose research focuses on the use of cannabidiol (CBD) to treat children suffering from epilepsy. He has previously directed a 3-year clinical study using synthetic CBD with over 65 patients. Leading Israeli epilepsy expert, Professor Uri Kramer, has previously directed a 3-year clinical study using whole plant extract with over 100 patients. Both clinical studies demonstrated a reduction in seizures experienced by approximately 50% of the study's participants.

Development of MGC Pharmaceuticals Registered Epilepsy Product

The results from the study will guide the Company's development of a future pharmaceutical grade product for the treatment of epilepsy that will use the Company's own proprietary formula and intellectual property. Following the clinical efficacy study, the Company aims to have the formula designated as a magisterial drug in Slovenia which allows Slovenian doctors to prescribe the product to sufferers of epilepsy. MGC Pharmaceuticals also intends to register the product as a medical product for sale across the European Union and other geographies, following the required legal and regulatory approvals. The Company plans to use the registered medical cannabis product for its future clinical studies and trials to be conducted around the world.

The registration and sale of a pharmaceutical product for the treatment of epilepsy presents a substantial commercial opportunity for MGC Pharmaceuticals. A registered pharmaceutical grade product has the potential to bring relief to millions of epilepsy sufferers across the globe. In Europe alone, there are close to 1 million children and young people with epilepsy and a further 2 million people aged between 20-64 suffering from epilepsy. Each year it is estimated that there are 130,000 new cases of epilepsy among children and adolescents in Europe¹.

Nativ Segev, Co-founder and Managing Director, MGC Pharmaceuticals commented:

"We look forward to the results of our clinical study on the efficacy of our medical cannabis formulation for the treatment of epilepsy in young people. We are confident that medical cannabis has the potential to bring relief to many people across the globe currently suffering with epilepsy.

"Additionally, the development of a cannabis-based product targeted at the relief of epilepsy presents a significant commercial opportunity for MGC Pharmaceuticals."

¹ [The epidemiology of epilepsy in Europe - a systematic review](#)

Professor Uri Kramer, Strategic Advisory Board Member, MGC Pharmaceuticals commented:

“This is an important cross-over study for investigating the efficacy of a whole plant extract medicinal cannabis formula with a high CBD/THC ratio for the treatment of children with refractory epilepsy from different etiologies. This test includes young people whose epilepsy has been previously unresponsive to several existing drugs.”

Dr David Neubauer commented:

“I look forward to working with MGC Pharmaceuticals and Professor Uri Kramer to conduct this study, which we believe has the potential to bring relief to sufferers of epilepsy. We are positive that whole plant extract formula will demonstrate superior results to a synthetic product.”

-- Ends --

For further information, please contact:

Media Enquiries

Ben Grubb
Account Director
Media and Capital Partners
+61 414 197 508
ben.grubb@mcpartners.com.au

MGC Pharmaceuticals Ltd

Brett Mitchell
Executive Chairman
+61 8 9389 2000
info@mgcpharma.com.au

About MXC

MGC Pharmaceuticals Ltd (ASX: MXC) is an EU based specialist medical cannabis company with many years of technical and commercial experience in the medical cannabis industry. The Company’s founders were key figures in the Israeli medical cannabis industry and the core business strategy is to develop and supply high quality non-psychoactive cannabidiol (CBD) resin extract for the growing demand in cosmetics and medical markets in Europe, North America and Australasia. The Company is also developing strategic joint ventures in these key value-add industries, as demonstrated with MGC Derma CBD cosmetics.